Skip to main content

CTMX

Stock
Health Care
Biotechnology

Performance overview

CTMX Price
Price Chart

Forward-looking statistics

Beta
2.03
Risk
95.81%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Company info

SectorHealth Care
IndustryBiotechnology
Employees139
Market cap$127.8M

Fundamentals

Enterprise value$111.3M
Revenue$147.6M
Revenue per employee
Profit margin28.19%
Debt to equity32.53

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.48
Dividend per share
Revenue per share$1.72
Avg trading volume (30 day)$7M
Avg trading volume (10 day)$6M
Put-call ratio

Macro factor sensitivity

Growth-1.8
Credit+8.3
Liquidity+1.1
Inflation-7.4
Commodities-2.9
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-4.31
Price to sales2.67
P/E Ratio-4.31
Enterprise Value to Revenue0.75
Price to book8.04

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day
Ex. dividend day

News

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

CytomX Therapeutics, Inc.'s CTMX share price was up 94.46% at last check on Monday.

Benzinga (May 12, 2025)
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free